This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
AKT3 / RAC-gamma serine/threonine-protein kinase · Western blot design guide
Design a Western Blot for AKT3
Real validated AKT3 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-AKT3 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
AKT3 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~55.8 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Caudate (IHC candidate; verify WB) +4 more | |
| Negative control | Salivary gland (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Glycosylated + Phosphorylated | |
| Caveat | Modification-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 2 isoform(s) |
Section 1
Real Curated AKT3 Western Blot Protocols
The A00520-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | Target-positive lysate and matched negative control (standard starting point) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A00520-1; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | goat anti-rabbit IgG, 1:5000 (catalog A00520-1) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected AKT3 Western Blot Band Size?
AKT3 is predicted at 55.8 kDa; its isoforms and modifications could affect migration, but no empirical band or feature-specific shift is established.
| Single band near 55.8 kDa | consistent with the predicted AKT3 mass; confirm identity with antibody controls |
| Two nearby bands | isoforms 1 and 2 are possible contributors, but distinct migration is unestablished |
| Band slightly offset from 55.8 kDa | O-linked GlcNAc or phosphorylation could affect migration; a visible shift is unestablished |
| Bands in nuclear and cytoplasmic fractions | consistent with AKT3 localization in both compartments |
💡Expected AKT3 appearanceAKT3 has a predicted mass of 55.8 kDa, with no empirical band size supplied; use antibody specificity controls to identify a band, since its modifications and isoforms have no demonstrated migration pattern here.
| UniProt predicted mass | places the reference band near 55.8 kDa |
| O-linked GlcNAc at Thr302 | adds GlcNAc; a visible shift is unestablished |
| O-linked GlcNAc at Thr309 | adds GlcNAc; a visible shift is unestablished |
| Alternate O-linked GlcNAc at Ser472 | adds GlcNAc when present; a visible shift is unestablished |
| Splice isoforms 1 and 2 | may differ in size; their relative masses and band separation are unspecified |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | AKT3 may be poorly recovered when membrane associated | check extraction and compare soluble and membrane fractions with an AKT3 positive control |
| Band higher than expected | modification could alter migration, but the cause is unestablished | verify identity with an independent AKT3 antibody and appropriate modification controls |
| Band lower than expected | an alternate isoform or fragment is possible; neither has a supplied mass | check antibody epitope coverage and compare with an independent AKT3 antibody |
| Multiple bands | isoforms 1 and 2 exist, but their separation on a blot is unestablished | compare bands using an independent antibody or isoform-specific controls |
| Weak or no signal | AKT3 recovery or antibody detection may be insufficient | check lysate loading, extraction and an AKT3 positive control |
Experiment evidence
Western blot images showing AKT3 band
A00520-1 · AKT3
A00520-2 · AKT3
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for AKT3 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for AKT3 in Western blot, you can use caudate tissue, which HPA rates as highly expressed.
Positive control: Caudate (IHC candidate; verify WB)
Negative control: Salivary gland (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: HPA identifies a high-expression tissue and a tissue where AKT3 is not detected, making tissue controls feasible.
HPA tissue expression evidence for AKT3
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Caudate | neuronal cells | High | Protein (IHC) | HPA → |
| Cerebral cortex | glial cells | High | Protein (IHC) | HPA → |
| Gallbladder | glandular cells | High | Protein (IHC) | HPA → |
| Hippocampus | neuronal cells | High | Protein (IHC) | HPA → |
| Nasopharynx | ciliated cells (ciliary rootlets) | High | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Salivary gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Spleen | cells in red pulp | Not detected | Protein (IHC) | HPA → |
| Adipose tissue | adipocytes | Low | Protein (IHC) | HPA → |
| Appendix | glandular cells | Low | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Low | Protein (IHC) | HPA → |
Section 3
Advanced AKT3 Western Blot Tips
Deeper troubleshooting and optimisation questions for AKT3, answered from its protein features.
What should I check when an unexpected AKT3 band appears?
Band shift · Check whether the antibody recognizes both isoforms: isoform 2 replaces canonical residues 452–479. Also check whether its epitope includes a listed modification site, especially residue 472 in that replaced region. The supplied features alone cannot identify an unexpected band.
Could AKT3 isoforms produce different bands?
Isoforms · UniProt lists isoforms 1 and 2. In isoform 2, canonical residues 452–479 are replaced by a shorter sequence, so isoform 2 may migrate differently. Whether both are detected depends on the antibody epitope; these features do not establish two visible bands.
Which AKT3 phosphorylation sites matter for a phospho-specific blot?
PTM · In the supplied UniProt coordinates, AKT3 has phosphothreonine at 305 by PDPK1 and at 447, plus phosphoserine at 472 by PKC/PRKCZ. Match the antibody’s stated site and numbering convention before interpreting its signal. Canonical residue 472 lies within the region replaced in isoform 2.
Can stimulation change AKT3 signal across cell fractions?
Induction · AKT3 is listed in the nucleus, cytoplasm and as a peripheral membrane protein. UniProt notes that stimulation leads to membrane association through translocation. Compare like fractions when measuring changes in AKT3 abundance or phosphorylation.
How should transfer be checked for AKT3?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A00520-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should AKT3 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Should AKT3 run at its predicted 55.8 kDa?
Interpretation · 55.8 kDa is the predicted mass for canonical AKT3; no observed band position is supplied. The listed modifications and isoforms do not, by themselves, establish a visible shift or explain any difference from that prediction.
UniProt lists O-linked GlcNAc at Thr302 and Thr309, and an alternate O-linked GlcNAc annotation at Ser472. Ser472 is also listed as phosphorylated. These annotations identify possible modification sites; they do not establish a detectable mass shift or identify the cause of an unexpected band.
UniProt states that TCL1A interacts with AKT3 through its PH domain and enhances AKT3 phosphorylation and activation. If comparing conditions with different TCL1A activity, measure phospho-AKT3 alongside total AKT3 to distinguish phosphorylation changes from changes in AKT3 abundance.
UniProt lists O-linked GlcNAc at Thr302 and Thr309, and an alternate O-linked GlcNAc annotation at Ser472. Ser472 is also listed as phosphorylated. These annotations identify possible modification sites; they do not establish a detectable mass shift or identify the cause of an unexpected band.
UniProt states that TCL1A interacts with AKT3 through its PH domain and enhances AKT3 phosphorylation and activation. If comparing conditions with different TCL1A activity, measure phospho-AKT3 alongside total AKT3 to distinguish phosphorylation changes from changes in AKT3 abundance.
Boster reagents
AKT3 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-AKT3 Antibody (Center)
Cat # A00520-1
Real WB data
Anti-AKT3 Antibody Picoband®
Cat # A00520-2
Both the supplier anti-AKT3 antibodies have WB images: A00520-1 in Jurkat lysate and A00520-2 in human, rat, and mouse lysates. A00520-2 shows an approximately 56 kDa band. The supplied evidence includes no publication or orthogonal validation.
Which to pick: Choose by sample: A00520-2 has WB images for SH-SY5Y, rat brain and C6, and mouse brain and Neuro-2a. A00520-1 has a Jurkat WB image and is the only listed antibody claiming monkey reactivity; no monkey WB sample is shown.
Source: BosterBio AKT3 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q9Y243.
- Human Protein Atlas. AKT3 tissue expression.
- PMC5722612 — target-verified WB comparison
- PMC4351658 — target-verified WB comparison
- PMC11884723 — target-verified WB comparison